File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Arterial wall: A new pharmacological and therapeutic target | LA PAROI ARTERIELLE: UNE NOUVELLE CIBLE PHARMACOLOGIQUE ET THERAPEUTIQUE?

TitleArterial wall: A new pharmacological and therapeutic target | LA PAROI ARTERIELLE: UNE NOUVELLE CIBLE PHARMACOLOGIQUE ET THERAPEUTIQUE?
Authors
KeywordsAngiotensin Ii Receptor Antagonists
Arterial Remodelling
Atherosclerosis
Endothelin Receptor Antagonists
Endothelium
Nitrates
No Donors
Potassium Channel Activators
Proteoglycans
Issue Date1995
PublisherAdis International Ltd. The Journal's web site is located at http://www.pharmacol-fr.org/therapie/
Citation
Therapie, 1995, v. 50 n. 4, p. 387-398 How to Cite?
AbstractIn recent years, endothelial dysfunction and arterial remodelling in various cardiovascular diseases have emerged as two key concepts, with numerous interrelationships. Both endothelial dysfunction and arterial remodelling occur in various pathologies including heart failure, atherosclerosis, restenosis after angioplasty, and pulmonary hypertension, and have modified the therapeutic approach by offering new pharmacological targets: specific receptors not only at the site of the vascular smooth muscle cells but also on the endothelial cells, growth factors that stimulate proliferation of smooth muscle, and receptors and enzymes of the extracellular matrix. Among the various substances under research, the present review will discuss angiotensin II receptor antagonists, endothelin receptor antagonists, nitrates-NO donors, potassium channel activators, and substances interfering with proteoglycans and other components of the extracellular matrix.
Persistent Identifierhttp://hdl.handle.net/10722/173526
ISSN
2015 Impact Factor: 0.776
2015 SCImago Journal Rankings: 0.183

 

DC FieldValueLanguage
dc.contributor.authorLaurent, Sen_US
dc.contributor.authorVanhoutte, Pen_US
dc.contributor.authorCavero, Ien_US
dc.contributor.authorChabrier, PEen_US
dc.contributor.authorDupuis, Ben_US
dc.contributor.authorElghozi, JLen_US
dc.contributor.authorHamon, Gen_US
dc.contributor.authorJaniak, Pen_US
dc.contributor.authorJuillet, Yen_US
dc.contributor.authorKher, Aen_US
dc.contributor.authorKoen, Ren_US
dc.contributor.authorMadonna, Oen_US
dc.contributor.authorMaffrand, JPen_US
dc.contributor.authorPruneau, Den_US
dc.contributor.authorThuillez, Cen_US
dc.contributor.authorMourad, JJen_US
dc.date.accessioned2012-10-30T06:32:31Z-
dc.date.available2012-10-30T06:32:31Z-
dc.date.issued1995en_US
dc.identifier.citationTherapie, 1995, v. 50 n. 4, p. 387-398en_US
dc.identifier.issn0040-5957en_US
dc.identifier.urihttp://hdl.handle.net/10722/173526-
dc.description.abstractIn recent years, endothelial dysfunction and arterial remodelling in various cardiovascular diseases have emerged as two key concepts, with numerous interrelationships. Both endothelial dysfunction and arterial remodelling occur in various pathologies including heart failure, atherosclerosis, restenosis after angioplasty, and pulmonary hypertension, and have modified the therapeutic approach by offering new pharmacological targets: specific receptors not only at the site of the vascular smooth muscle cells but also on the endothelial cells, growth factors that stimulate proliferation of smooth muscle, and receptors and enzymes of the extracellular matrix. Among the various substances under research, the present review will discuss angiotensin II receptor antagonists, endothelin receptor antagonists, nitrates-NO donors, potassium channel activators, and substances interfering with proteoglycans and other components of the extracellular matrix.en_US
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://www.pharmacol-fr.org/therapie/en_US
dc.relation.ispartofTherapieen_US
dc.subjectAngiotensin Ii Receptor Antagonistsen_US
dc.subjectArterial Remodellingen_US
dc.subjectAtherosclerosisen_US
dc.subjectEndothelin Receptor Antagonistsen_US
dc.subjectEndotheliumen_US
dc.subjectNitratesen_US
dc.subjectNo Donorsen_US
dc.subjectPotassium Channel Activatorsen_US
dc.subjectProteoglycansen_US
dc.titleArterial wall: A new pharmacological and therapeutic target | LA PAROI ARTERIELLE: UNE NOUVELLE CIBLE PHARMACOLOGIQUE ET THERAPEUTIQUE?en_US
dc.typeConference_Paperen_US
dc.identifier.emailVanhoutte, P:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, P=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-0029084494en_US
dc.identifier.volume50en_US
dc.identifier.issue4en_US
dc.identifier.spage387en_US
dc.identifier.epage398en_US
dc.publisher.placeNew Zealanden_US
dc.identifier.scopusauthoridLaurent, S=7102779577en_US
dc.identifier.scopusauthoridVanhoutte, P=7202304247en_US
dc.identifier.scopusauthoridCavero, I=7006668310en_US
dc.identifier.scopusauthoridChabrier, PE=7005988764en_US
dc.identifier.scopusauthoridDupuis, B=7005189900en_US
dc.identifier.scopusauthoridElghozi, JL=7006937210en_US
dc.identifier.scopusauthoridHamon, G=7003320119en_US
dc.identifier.scopusauthoridJaniak, P=6603686655en_US
dc.identifier.scopusauthoridJuillet, Y=7005174082en_US
dc.identifier.scopusauthoridKher, A=36917111000en_US
dc.identifier.scopusauthoridKoen, R=6603112958en_US
dc.identifier.scopusauthoridMadonna, O=6602744871en_US
dc.identifier.scopusauthoridMaffrand, JP=7005521190en_US
dc.identifier.scopusauthoridPruneau, D=7005510301en_US
dc.identifier.scopusauthoridThuillez, C=7005267110en_US
dc.identifier.scopusauthoridMourad, JJ=7006408071en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats